131 related articles for article (PubMed ID: 38711180)
21. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
Errani C; Tsukamoto S; Leone G; Righi A; Akahane M; Tanaka Y; Donati DM
J Bone Joint Surg Am; 2018 Mar; 100(6):496-504. PubMed ID: 29557866
[TBL] [Abstract][Full Text] [Related]
22. Effect evaluation of denosumab combined with curettage and bone cement reconstruction in the treatment of recurrent giant cell tumor of bone around the knee joint.
Duan DK; Zhang GC; Sun BJ; Ma TX; Zhao M
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5039-5052. PubMed ID: 37318478
[TBL] [Abstract][Full Text] [Related]
23. Supplemental Bone Grafting in Giant Cell Tumor of the Extremity Reduces Nononcologic Complications.
Benevenia J; Rivero SM; Moore J; Ippolito JA; Siegerman DA; Beebe KS; Patterson FR
Clin Orthop Relat Res; 2017 Mar; 475(3):776-783. PubMed ID: 26932739
[TBL] [Abstract][Full Text] [Related]
24. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
[TBL] [Abstract][Full Text] [Related]
25. Giant cell tumor of bone: treatment and outcome of 214 cases.
Balke M; Schremper L; Gebert C; Ahrens H; Streitbuerger A; Koehler G; Hardes J; Gosheger G
J Cancer Res Clin Oncol; 2008 Sep; 134(9):969-78. PubMed ID: 18322700
[TBL] [Abstract][Full Text] [Related]
26. Giant cell tumor of extremities, surgical treatment and local adjuvants: which is the most effective?
Colangeli S; Del Chiaro A; Andreani L; D'Arienzo A; Parchi P; Capanna R
J Biol Regul Homeost Agents; 2020; 34(5 Suppl. 1):57-62. IORS Special Issue on Orthopedics. PubMed ID: 33739006
[TBL] [Abstract][Full Text] [Related]
27. Novel Strategy of Curettage and Adjuvant Microwave Therapy for the Treatment of Giant Cell Tumor of Bone in Extremities: A Preliminary Study.
Ke J; Cheng S; Yao MY; Chu X; Wang M; Zeng XL; Yang T; Zhang C; Zhong H; Zhang Y
Orthop Surg; 2021 Feb; 13(1):185-195. PubMed ID: 33442922
[TBL] [Abstract][Full Text] [Related]
28. Curettage as first surgery for bone giant cell tumor : adequate surgery is more important than oncology training or surgical management by high volume specialized teams.
Tsukamoto S; Mavrogenis AF; Tanzi P; Leone G; Akahane M; Tanaka Y; Errani C
Eur J Orthop Surg Traumatol; 2020 Jan; 30(1):3-9. PubMed ID: 31520122
[TBL] [Abstract][Full Text] [Related]
29. Intralesional treatment versus wide resection for central low-grade chondrosarcoma of the long bones.
Dierselhuis EF; Goulding KA; Stevens M; Jutte PC
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD010778. PubMed ID: 30845364
[TBL] [Abstract][Full Text] [Related]
30. Ethanol as a local adjuvant for giant cell tumor of bone.
Jones KB; DeYoung BR; Morcuende JA; Buckwalter JA
Iowa Orthop J; 2006; 26():69-76. PubMed ID: 16789453
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
[TBL] [Abstract][Full Text] [Related]
32. Extended intralesional curettage preferred over resection-arthrodesis for giant cell tumour of the distal radius.
Abuhejleh H; Wunder JS; Ferguson PC; Isler MH; Mottard S; Werier JA; Griffin AM; Turcotte RE
Eur J Orthop Surg Traumatol; 2020 Jan; 30(1):11-17. PubMed ID: 31297594
[TBL] [Abstract][Full Text] [Related]
33. Intralesional curettage for grades II and III giant cell tumors of bone.
Lackman RD; Hosalkar HS; Ogilvie CM; Torbert JT; Fox EJ
Clin Orthop Relat Res; 2005 Sep; 438():123-7. PubMed ID: 16131880
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant therapy by high-speed burr may cause intraoperative bone tumor seeding: an animal study.
Wang PH; Wu CL; Chen CM; Wang JY; Wu PK; Chen WM
BMC Musculoskelet Disord; 2020 Jul; 21(1):507. PubMed ID: 32736546
[TBL] [Abstract][Full Text] [Related]
35. Mid-term outcome after curettage with polymethylmethacrylate for giant cell tumor around the knee: higher risk of radiographic osteoarthritis?
van der Heijden L; van de Sande MA; Heineken AC; Fiocco M; Nelissen RG; Dijkstra PD
J Bone Joint Surg Am; 2013 Nov; 95(21):e159. PubMed ID: 24196471
[TBL] [Abstract][Full Text] [Related]
36. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
Tsukamoto S; Tanaka Y; Mavrogenis AF; Kido A; Kawaguchi M; Errani C
Clin Orthop Relat Res; 2020 May; 478(5):1076-1085. PubMed ID: 31794487
[TBL] [Abstract][Full Text] [Related]
37. Similar local recurrence but better function with curettage versus resection for bone giant cell tumor and pathological fracture at presentation.
Tsukamoto S; Mavrogenis AF; Tanzi P; Leone G; Righi A; Akahane M; Kido A; Honoki K; Tanaka Y; Donati DM; Errani C
J Surg Oncol; 2019 Jun; 119(7):864-872. PubMed ID: 30734307
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture.
Medellin MR; Fujiwara T; Tillman RM; Jeys LM; Gregory J; Stevenson JD; Parry M; Abudu A
Bone Joint J; 2018 Dec; 100-B(12):1626-1632. PubMed ID: 30499317
[TBL] [Abstract][Full Text] [Related]
39. [Meta-analysis of risk factors of recurrence in patients with giant cell tumor on extremities].
Li R; Hu Y
Zhonghua Yi Xue Za Zhi; 2014 Dec; 94(47):3778-83. PubMed ID: 25623108
[TBL] [Abstract][Full Text] [Related]
40. Giant cell tumor with pathologic fracture: should we curette or resect?
van der Heijden L; Dijkstra PD; Campanacci DA; Gibbons CL; van de Sande MA
Clin Orthop Relat Res; 2013 Mar; 471(3):820-9. PubMed ID: 22926445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
